Table 3.

Pregnancy outcomes by SLE clinical disease activity and presence of the anti-dsDNA antibody, based on measurements made at each trimester. Only women observed during the trimester of pregnancy under study were included in each group.

Low-activity SLEHigh-activity SLEp
Anti-dsDNA Absent (%)Anti-dsDNA Present (%)Anti-dsDNA Absent (%)Anti-dsDNA Present (%)Compares All 4 GroupsCompares Low and High ActivityCompares with/without Anti-dsDNA
First trimester
  N926139
  Fetal loss12 (13)10 (16)1 (33)4 (44)0.460.0490.29
  Preterm*30 (38)22 (43)04 (80)Too few**Too few**0.27
  SGA12 (15)8 (16)1 (50)2 (40)Too few**Too few**0.77
Second trimester
  N131631316
  Fetal loss6 (5)8 (13)3 (23)3 (19)0.110.0190.039
  Preterm*39 (31)23 (42)7 (70)11 (85)0.00290.00030.032
  SGA25 (20)12 (22)2 (20)2 (15)0.960.710.94
Third trimester
  N12162219
  Fetal loss1 (1)0 (0)3 (14)0 (0)Too few**Too few**Too few**
  Preterm*40 (33)26 (42)11 (61)4 (44)0.170.0610.45
  SGA24 (20)15 (24)8 (44)0 (0)0.180.360.69
  • * Percentages are of live births that were preterm (delivered prior to 37 weeks gestation).

  • ** Too few events to allow statistical analysis.

  • Small for gestational age: birth weight < 10th percentile for gestational age. SLE: systemic lupus erythematosus.